EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Diagnostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in Differentiating Primary From Serious Secondary Headache

Sara-Jessica Camerin, Cihan Atila iD, Claudine A Blum, Sofia Sandgren, Aleksandra Maleska, Athina Papadopoulou, Jens Kuhle iD, Mira Katan, Mirjam Christ-Crain iD

European Journal of Neurology · 2026-07 · 33 (7)

DOI: 10.1111/ene.70691 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 06.07.2026. Verfasst von Sara-Jessica Camerin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Neurofilament Proteins, Headache Disorders, Secondary, Headache Disorders, Primary. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Foundation, Nora van Meeuwen Häfliger Stiftung, Gottfried und Julia Bangerter-Rhyner-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Headache is one of the most frequent reasons for emergency department (ED) visits, and distinguishing primary from secondary headache remains challenging. Blood biomarkers may improve early risk stratification. This study evaluates serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) as potential biomarkers in patients presenting with non‐traumatic headache to the ED.

Methods

Secondary analysis of a prospective multicenter case–control study at University Hospital Basel and Aarau, Switzerland. Patients presenting with acute non‐traumatic headache were included. Final headache diagnoses were adjudicated by two board‐certified neurologists. Blood samples obtained at ED presentation were analyzed for sNfL and sGFAP, excluding patients with conditions known to affect biomarker levels. Primary headache samples were matched to serious secondary headache samples. Biomarker levels were expressed as age‐, BMI‐, and sex‐adjusted Z‐scores.

Results

A total of 82 patients were analyzed (42 serious secondary, 40 primary headache). Median[IQR] sNfL Z ‐scores were significantly higher in serious secondary compared with primary headache (0.8 [0.0–1.8] vs. 0.2 [−0.3–0.8]; p < 0.01). sGFAP Z‐scores showed an even greater difference (1.2 [−0.1–2.3] vs. −0.2 [−0.7–0.2]; p < 0.001). Both biomarkers demonstrated a specificity of 85%, but sGFAP showed higher sensitivity (57% vs. 43%), NPV (65% vs. 59%), and PPV (80% vs. 75%). In multivariable analysis adjusted for clinical risk factors, sGFAP remained independently associated with serious secondary headache (OR 1.9, 95%‐CI 1.2–3.4), whereas sNfL did not. Discussion sGFAP may represent a promising biomarker to support differentiation between primary and non‐traumatic serious secondary headache in the ED, warranting validation in larger cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glial Fibrillary Acidic ProteinNeurofilament ProteinsHeadache Disorders, SecondaryHeadache Disorders, PrimaryHumansFemaleMaleBiomarkersMiddle AgedDiagnosis, DifferentialCase-Control StudiesAdultProspective StudiesAged

Stichwörter der Autor:innen

GFAPNfLdiagnosticdifferentiationheadachenon‐traumatic brain injuryprimary headacheserious secondary headache

Substanzen

Glial Fibrillary Acidic ProteinNeurofilament ProteinsBiomarkersneurofilament protein LGFAP protein, human

Autor:innen und Institutionen

  • Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.
  • Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland.
  • Multiple Sclerosis Centre and Research Centre for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Department of Neurology, University of Basel, University Hospital Basel, Basel, Switzerland.

ORCID-Profile: Cihan Atila, Jens Kuhle, Mirjam Christ-Crain

Förderung

  • Swiss National Foundation
  • Nora van Meeuwen Häfliger Stiftung
  • Gottfried und Julia Bangerter-Rhyner-Stiftung
  • the Vizerektorat of the University Basel

Zitieren

APA

Camerin, S. J., Atila, C., Blum, C. A., Sandgren, S., Maleska, A., Papadopoulou, A., Kuhle, J., Katan, M., & Christ-Crain, M. (2026). Diagnostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in Differentiating Primary From Serious Secondary Headache. European Journal of Neurology, 33(7). https://doi.org/10.1111/ene.70691

Vancouver

Camerin SJ, Atila C, Blum CA, Sandgren S, Maleska A, Papadopoulou A, et al. Diagnostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in Differentiating Primary From Serious Secondary Headache. European Journal of Neurology. 2026;33(7). doi:10.1111/ene.70691

BibTeX
@article{Camerin2026,
  author = {Camerin, Sara-Jessica and Atila, Cihan and Blum, Claudine A and Sandgren, Sofia and Maleska, Aleksandra and Papadopoulou, Athina and Kuhle, Jens and Katan, Mira and Christ-Crain, Mirjam},
  title = {Diagnostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in Differentiating Primary From Serious Secondary Headache},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {7},
  doi = {10.1111/ene.70691}
}
Kostenlos starten →